Cargando…

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study

OBJECTIVE: To investigate the long-term safety and efficacy of weekly subcutaneous IgPro20 (Hizentra, CSL Behring) in chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: In a 48-week open-label prospective extension study to the PATH study, patients were initially started on 0.2 g/kg...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Schaik, Ivo N., Mielke, Orell, Bril, Vera, van Geloven, Nan, Hartung, Hans-Peter, Lewis, Richard A., Sobue, Gen, Lawo, John-Philip, Praus, Michaela, Durn, Billie L., Cornblath, David R., Merkies, Ingemar S. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624149/ https://www.ncbi.nlm.nih.gov/pubmed/31355323 http://dx.doi.org/10.1212/NXI.0000000000000590

Ejemplares similares

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
por: Merkies, Ingemar S.J., et al.
Publicado: (2019)

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial
por: van Schaik, Ivo N., et al.
Publicado: (2016)

Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Merkies, Ingemar S. J., et al.
Publicado: (2022)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review
por: Lewis, Richard A., et al.
Publicado: (2020)

Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial
por: Merkies, Ingemar S. J., et al.
Publicado: (2017)

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)

Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions
por: Gingele, Stefan, et al.
Publicado: (2021)

Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
por: Kanegane, Hirokazu, et al.
Publicado: (2014)

Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post‐hoc analysis of the immunoglobulin overtreatment in CIDP trial
por: van Veen, Robin, et al.
Publicado: (2022)

Treatment Approaches for Atypical CIDP
por: Menon, Deepak, et al.
Publicado: (2021)

Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency
por: Rojavin, Mikhail A., et al.
Publicado: (2019)

A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol
por: Cornblath, David R., et al.
Publicado: (2018)

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
por: Hagan, John B., et al.
Publicado: (2010)

Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports
por: Shebl, Amgad, et al.
Publicado: (2020)

Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study
por: Anderson, John T., et al.
Publicado: (2021)

Safety and Tolerability of Manual Push Administration of Subcutaneous IgPro20 at High Infusion Rates in Patients with Primary Immunodeficiency: Findings from the Manual Push Administration Cohort of the HILO Study
por: Cowan, Juthaporn, et al.
Publicado: (2020)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

NK cell markers predict the efficacy of IV immunoglobulins in CIDP
por: Mausberg, Anne K., et al.
Publicado: (2020)

Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern
por: Eftimov, Filip, et al.
Publicado: (2014)

Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy
por: Cornblath, David R, et al.
Publicado: (2022)

Real‐world results with IgPro20 for hypo‐ or agammaglobulinemia in Japan
por: Imai, Kohsuke, et al.
Publicado: (2022)

Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination
por: Abraham, Alon, et al.
Publicado: (2015)

Comparison of diabetes patients with “demyelinating” diabetic sensorimotor polyneuropathy to those diagnosed with CIDP
por: Dunnigan, Samantha K, et al.
Publicado: (2013)

The comparison of MRN, electrophysiology and progression among typical CIDP and atypical CIDP subtypes
por: Feng, Yuan, et al.
Publicado: (2020)

The Misdiagnosis of CIDP: A Review
por: Allen, Jeffrey A.
Publicado: (2020)

Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design
por: Deng, Chunqin, et al.
Publicado: (2011)

A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
por: Mallick, Rajiv, et al.
Publicado: (2023)

Clinical outcome of CIDP one year after start of treatment: a prospective cohort study
por: Bus, S. R. M., et al.
Publicado: (2021)

Severe CIDP-MGUS responsive to Rituximab
por: Posa, Andreas, et al.
Publicado: (2020)

CIDP mimics: a case series
por: Moshe-Lilie, Orly, et al.
Publicado: (2021)

Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale
por: Barnett, Carolina, et al.
Publicado: (2015)

Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP
por: Markvardsen, Lars Kjøbsted, et al.
Publicado: (2019)

The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP
por: Burt, Richard K., et al.
Publicado: (2021)

Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates
por: Abraham, Alon, et al.
Publicado: (2015)

MRI biomarkers of proximal nerve injury in CIDP
por: Lichtenstein, Thorsten, et al.
Publicado: (2017)

Progress in Hematopoietic Stem Cell Transplantation for CIDP
por: Qin, Zhen, et al.
Publicado: (2020)

Editorial: Update on the Diagnosis and Management of CIDP Variants
por: Chroni, Elisabeth, et al.
Publicado: (2021)

The neurophysiological lesson from the Italian CIDP database
por: Spina, Emanuele, et al.
Publicado: (2021)

Serum Contactin-1 in CIDP: A Cross-Sectional Study
por: Wieske, Luuk, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6hmjllspvp3cftqmah2n3hu3dn